NeoGenomics Reports Q4 2024 Earnings with Revenue Growth and Margin Improvements
NeoGenomics (NEO) reported Q4 2024 revenue of $172 million, an 11% increase, with improved adjusted gross margin to 48%. The company also announced full-year 2024 revenue of $661 million and guidance for 2025 revenue of $735 million to $745 million.
Tickers: $NEO
Topics: clinical testing earnings EBITDA guidance NGS revenue partnerships revenue growth